STOCK TITAN

BLFS officer sale: 419 shares at $27.36; holdings now 193,253

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

BioLife Solutions (BLFS) reported an insider transaction by its Chief Quality and Operations officer. On 10/09/2025, the reporting person sold 419 shares of common stock at $27.36 per share in a transaction coded “S.” The filing states this sale was made under a Rule 10b5-1(c) trading plan adopted effective 01-03-2023 to satisfy tax withholding obligations upon the vesting of restricted stock.

Following the sale, the reporting person beneficially owned 193,253 shares, held directly.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Foster Karen A.

(Last) (First) (Middle)
3303 MONTE VILLA PARKWAY
SUITE 310

(Street)
BOTHELL WA 98021

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Quality and Operations
3. Date of Earliest Transaction (Month/Day/Year)
10/09/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/09/2025 S(1) 419 D $27.36 193,253 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.
Remarks:
/s/ Karen A. Foster 10/14/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did BLFS report in this Form 4?

A company officer reported selling 419 shares of common stock at $27.36 on 10/09/2025.

How many BLFS shares does the reporting person now own?

After the transaction, the reporting person beneficially owned 193,253 shares, held directly.

Was the BLFS sale under a 10b5-1 plan?

Yes. The sale was made under a Rule 10b5-1(c) plan adopted effective 01-03-2023.

What was the purpose of the BLFS share sale?

The filing states it was to satisfy tax withholding obligations related to vesting of restricted stock.

Who is the BLFS reporting person’s role?

The reporting person is an Officer, titled Chief Quality and Operations.

What was the transaction code for the BLFS sale?

It was coded S (sale).
Biolife Solutions Inc

NASDAQ:BLFS

BLFS Rankings

BLFS Latest News

BLFS Latest SEC Filings

BLFS Stock Data

1.05B
47.19M
2.11%
104.51%
8.23%
Medical Instruments & Supplies
Electromedical & Electrotherapeutic Apparatus
Link
United States
BOTHELL